This inventor holds 3 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignee: Hoffmann-La Roche Inc.. Active years: 2018-2024.
Company Filing History:
Years Active: 2018-2024
Title: Martin Ebeling: Innovator in RNA Research
Introduction
Martin Ebeling is a notable inventor based in Grenzach-Wyhlen, Germany. He has made significant contributions to the field of molecular biology, particularly in the development of oligonucleotides and cancer treatment methodologies. With a total of 3 patents, Ebeling's work has the potential to impact therapeutic strategies significantly.
Latest Patents
Ebeling's latest patents include innovative approaches to targeting RNA binding protein sites. His invention relates to antisense oligonucleotides that are complementary to conserved TDP-43 binding sites on pre-mRNA transcripts. These oligonucleotides are capable of restoring RNA binding protein function in the processing of multiple independent mRNAs in TDP-43 depleted cells. Additionally, he has developed a screening method for identifying new compounds for use in cancer treatment, showcasing his commitment to advancing medical research.
Career Highlights
Throughout his career, Martin Ebeling has worked with prominent companies in the pharmaceutical industry, including Hoffmann-La Roche Inc. and F. Hoffmann-La Roche AG. His experience in these organizations has allowed him to collaborate on various innovative projects that aim to improve health outcomes.
Collaborations
Ebeling has collaborated with esteemed colleagues such as Friedrich Metzger and Manaswini Sivaramakrishnan. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in research.
Conclusion
Martin Ebeling's contributions to RNA research and cancer treatment exemplify the impact of innovation in the scientific community. His patents and collaborations reflect a dedication to improving therapeutic strategies and advancing our understanding of molecular biology.